Galmed Pharmaceuticals Ltd
GLMD
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.35M
Close$
$0.92
50% upside
Current Fair Value
50% upsideUndervalued by 50% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.35 Million |
|---|---|
| Enterprise Value | $-631,711.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.39 |
| Beta | 0.71 |
| Outstanding Shares | 6,581,390 |
Return
| Return on Equity | -65.32% |
|---|---|
| Return on Assets | -55.34% |
| Return on Invested Capital | -53.92% |
Valuation & Multiples
| P/E Ratio | -0.39 |
|---|---|
| PEG | -0.78 |
| Price to Sales | - |
| Price to Book Ratio | 0.31 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.07 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 20, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
July 30, 2026
EPS Estimate
$-0.39
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Galmed Pharmaceuticals Ltd
CEO: Allen Baharaff Galmed Pharmaceuticals Ltd. is a clinical stage drug development biopharmaceutical company for liver, metabolic and inflammatory diseases. Its lead compound, Aramchol™, a backbone drug candidate for the treatment of NASH and fibrosis is ...